| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 05-15-2024 | 03-31-2024 | 10-Q | |
| 2 | 04-01-2024 | 12-31-2023 | 10-K | |
| 3 | 10-27-2023 | 09-30-2023 | 10-Q | |
| 4 | 07-28-2023 | 06-30-2023 | 10-Q | |
| 5 | 05-10-2023 | 03-31-2023 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Mangoceuticals (NASDAQ:MGRX) reported quarterly losses of $(0.10) per share. This is a 56.52 percent increase over losses of $(...
Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, a...
Signifies the first major step towards the application process for the certification of itsMango ED oral dissolvable products b...
Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today’s pre-market trading following fourth-quarter re...
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a y...
The Dallas Based, Direct-to-Consumer Telemedicine Company Brings the FDA-Approved Oral Testosterone Replacement Therapy Treatme...
Newly developed clinic prescribing system will allow Doctors to prescribe MangoRx products from within practices and clinics
